|
1
|
Altekuse SF, Kosary CL, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2007. NCI; Bethesda: 2010
|
|
2
|
Grieb G, Merk M, Bernhagen J and Bucala R:
Macrophage migration inhibitory factor (MIF): a promising
biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santos LL and Morand EF: Macrophage
migration inhibitory factor: a key cytokine in RA, SLE and
atherosclerosis. Clin Chim Acta. 399:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy H, Mawhinney L and Donnelly SC:
Inflammation and cancer: macrophage migration inhibitory factor
(MIF) - the potential missing link. QJM. 103:831–836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitchell RA: Mechanisms and effectors of
MIF-dependent promotion of tumourigenesis. Cell Signal. 16:13–19.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rendon BE, Willer SS, Zundel W and
Mitchell RA: Mechanisms of macrophage migration inhibitory factor
(MIF)-dependent tumor microenvironmental adaptation. Exp Mol
Pathol. 3:180–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tarnowski M, Grymula K, Liu R, et al:
Macrophage migration inhibitory factor is secreted by
rhabdomyosarcoma cells, modulates tumor metastasis by binding to
CXCR4 and CXCR7 receptors and inhibits recruitment of
cancer-associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010.
View Article : Google Scholar
|
|
8
|
Martinez LM, Vallone VB F, Labovsky V, et
al: Changes in the peripheral blood and bone marrow from untreated
advanced breast cancer patients that are associated with the
establishment of bone metastases. Clin Exp Metastasis. 31:213–232.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lue H, Thiele M, Franz J, et al:
Macrophage migration inhibitory factor (MIF) promotes cell survival
by activation of the AKT pathway and role for CSN5/JAB1 in the
control of autocrine MIF activity. Oncogene. 26:5046–5059. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bernhagen J, Krohn R, Lue H, et al: MIF is
a noncognate ligand of CXC chemokine receptors in inflammatory and
atherogenic cell recruitment. Nat Med. 13:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zernecke A, Bernhagen J and Weber C:
Macrophage migration inhibitory factor in cardiovascular disease.
Circulation. 117:1594–1602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell RA, Liao H, Chesney J,
Fingerle-Rowson G, Baugh J, David J and Bucala R: Macrophage
migration inhibitory factor (MIF) sustains macrophage
proinflammatory function by inhibiting p53: regulatory role in the
innate immune response. Proc Natl Acad Sci USA. 99:345–350. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fersching DMI, Nagel D, Siegele B, Salat
C, Heinemann V, Holdenrieder S and Stoetzer OJ: Apoptosis-related
biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer
patients undergoing neoadjuvant chemotherapy. Anticancer Res.
32:2047–2058. 2012.PubMed/NCBI
|
|
14
|
Verjans E, Noetzel E, Bektas N, et al:
Dual role of macrophage migration inhibitory factor (MIF) in human
breast cancer. BMC Cancer. 9:2302009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bando H, Matsumoto G, Bando M, et al:
Expression of macrophage migration inhibitory factor in human
breast cancer: association with nodal spread. Jnp J Cancer Res.
93:389–396. 2002.PubMed/NCBI
|
|
16
|
Xu X, Wang B, Ye C, et al: Overexpression
of macrophage migration inhibitory factor induces angiogenesis in
human breast cancer. Cancer Lett. 261:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian B, Zhang Y, Li N, Liu X and Dong J:
CD74: a potential novel target for triple-negative breast cancer.
Tumour Biol. 33:2273–2277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greenwood C, Metodieva G, Al-Janabi K, et
al: Stat1 and CD74 overexpression is co-dependent and linked to
increased invasion and lymph node metastasis in triple-negative
breast cancer. J Proteomics. 75:3031–3040. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Metodieva G, Correa Nogueira-de-Souza N,
Greenwood C, Al-Janabi K, Leng L, Bucala R and Metodiev MV:
CD74-dependent deregulation of the tumor suppressor scribble in
human epithelial and breast cancer cells. Neoplasia. 15:660–668.
2013.PubMed/NCBI
|
|
20
|
Schulz R, Marchenko ND, Holemboswki, et
al: Inhibiting the HSP90 chaperone destabilizes macrophage
migration inhibitory factor and thereby inhibits breast tumor
progression. J Exp Med. 209:275–289. 2012. View Article : Google Scholar
|
|
21
|
Govindan SV, Cardillo TM, Sharkey RM, Tat
F, Gold DV and Goldenberg DM: Milatuzumab-SN-38 conjugates for the
treatment of CD74+cancers. Mol Cancer Ther. 12:968–978.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hammond EH, Hayes DF, Dowsett M, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for immunohistochemical
testing of estrogen and progesterone receptors in breast cancer
(unabridged version). Arch Pathol Lab Med. 134:48–72. 2010.
|
|
23
|
Dowset M, Nielsen TO, A’Hern R, et al:
Assesment of Ki67 in breast cancer: recommendations from the
international Ki67 in breast cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schrohl AS, Pedersen HC, Jensen SS,
Nielsen S and Brünner N: Human epidermal growth factor receptor
(HER2) immunoreactivity: specificity of three pharmacodiagnostic
antibodies. Histopathology. 59:975–983. 2011. View Article : Google Scholar
|
|
25
|
Preat F, Simon P and Noel JC: Differences
in breast carcinoma immunohistochemical subtypes between immigrant
Arab and European women. Diagn Pathol. 9:262014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cludts S, Decaestecker Ch, Johnson B, et
al: Increased expression of macrophage migration inhibitory factor
during progression to hypopharyngeal squamous cell carcinoma.
Anticancer Res. 30:3313–3319. 2010.PubMed/NCBI
|
|
27
|
Kindt N, Lechien J, Decaestecker C, et al:
Expression of macrophage migration-inhibitory factor is correlated
with progression in oral cavity carcinomas. Anticancer Res.
32:4499–4505. 2012.PubMed/NCBI
|
|
28
|
Jesneck JL, Mukherjee S, Yurkovetsky Z,
Clyde M, Marks JR, Lorkshin AE and Lo JY: Do serum biomarkers
really measure breast cancer? BMC Cancer. 9:1642009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Simpson KD, Templeton DJ and Cross JV:
Macrophage migration inhibitory factor promotes tumor growth and
metastasis by inducing myeloid-derived suppressor cells in the
tumor microenvironment. J Immunol. 189:5533–5540. 2012. View Article : Google Scholar
|
|
30
|
Kim H, Lee S, Kim JH, et al: Elevated
levels of macrophage migration inhibitory factor in women with
metabolic syndrome. Horm Metab Res. 43:642–645. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kolar M, Szabo P, Dvorankova B, et al:
Upregulation of IL-6, IL-8 and CXCL-1 production in dermal
fibroblasts by normal/malignant epithelial cells in vitro:
Immunohistochemical and transcriptomic analyses. Bio Cell.
104:738–751. 2012. View Article : Google Scholar
|
|
32
|
Catteau X, Simon P, Vanhaeverbeek M and
Noël JC: Variable stromal periductal expression of CD34 and smooth
muscle actin (SMA) in intraductal carcinoma of the breast. PLoS
One. 8:e57732013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meyer-Siegler KL, Iczkowski KA and Vera
PL: Further evidence for increased macrophage migration inhibitory
factor expression in prostate cancer. BMC Cancer. 5:732005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McClelland M, Zhao L, Carskadon S and
Arenberg D: Expression of CD74, the receptor for macrophage
migration inhibitory factor, in non-small cell lung cancer. Am J
Pathol. 174:638–646. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
von Minckwitz G, Eidtmann H, Rezai M, et
al: Neoadjuvant chemotherapy and bevacizumab for HER-2 negative
breast cancer. N Engl J Med. 366:299–309. 2012.PubMed/NCBI
|
|
36
|
Simpsons KD and Cross JV: MIF
metastasis/MDSC-inducing factor? Oncoimmunology. 2:32013.PubMed/NCBI
|
|
37
|
Zhang L, Ye SB, Ma G, et al: The
expressions of MIF and CXCR4 protein in tumor microenvironment are
adverse prognostic factors in patients with esophageal squamous
cell carcinoma. J Transl Med. 11:602013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Du W, Wright BM, Li X, et al:
Tumor-derived macrophage migration inhibitory factor promotes an
autocrine loop that enhances renal cell carcinoma. Oncogene.
32:1469–1474. 2013. View Article : Google Scholar : PubMed/NCBI
|
